J K Waselenko Selected Research

Hypoxia (Hypoxemia)

4/2001

Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

J K Waselenko Research Topics

Disease

6	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 09/2001 - 04/2000
1	Leukemia 06/2001
1	Dyspnea (Shortness of Breath) 04/2001
1	Hypotension (Low Blood Pressure) 04/2001
1	Hypoxia (Hypoxemia) 04/2001
1	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 04/2000
1	Neoplasms (Cancer) 04/2000

Drug/Important Bio-Agent (IBA)

2	Chlorambucil (Leukeran)FDA Link 04/2000 - 04/2000
2	Pentostatin (Nipent)FDA LinkGeneric 04/2000 - 04/2000
1	carboxyamido-triazole (carboxyamidotriazole)IBA 09/2001
1	Gemcitabine FDA Link 06/2001
1	Rituximab (Mabthera)FDA Link 04/2001
1	Interleukin-8 (Interleukin 8)IBA 04/2001
1	Interferon-gamma (Interferon, gamma)IBA 04/2001
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 04/2001
1	Interleukin-6 (Interleukin 6)IBA 04/2001
1	A-Form DNA (A-DNA)IBA 04/2000
1	purineIBA 04/2000
1	Alkylating AgentsIBA 04/2000
1	Biological ProductsIBA 04/2000
1	Phosphodiesterase InhibitorsIBA 04/2000
1	Theophylline (Theon)FDA LinkGeneric 04/2000
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 04/2000
1	fludarabineIBA 04/2000

Therapy/Procedure

3	Therapeutics 06/2001 - 04/2000